Efficient ultrasound focusing

Information

  • Patent Grant
  • 8932237
  • Patent Number
    8,932,237
  • Date Filed
    Wednesday, April 28, 2010
    14 years ago
  • Date Issued
    Tuesday, January 13, 2015
    10 years ago
Abstract
Ultrasound focusing may be improved by combining knowledge of the target tissue and/or focusing arrangement with focus measurements.
Description
FIELD OF THE INVENTION

The present invention relates, generally, to systems and methods for ultrasound focusing. In particular, various embodiments are directed to efficient methods of focusing a phased array of ultrasound transducer elements, using both model-based computations and measurements of focus quality to adjust the relative phases of the transducer elements.


BACKGROUND

Focused ultrasound (i.e., acoustic waves having a frequency greater than about 20 kilohertz) can be used to image or therapeutically treat internal body tissues within a patient. For example, ultrasonic waves may be used to ablate tumors, eliminating the need for the patient to undergo invasive surgery. For this purpose, a piezo-ceramic transducer is placed externally to the patient, but in close proximity to the tissue to be ablated (the “target”). The transducer converts an electronic drive signal into mechanical vibrations, resulting in the emission of acoustic waves (a process hereinafter referred to as “sonication”). The transducer may be shaped so that the waves converge in a focal zone. Alternatively or additionally, the transducer may be formed of a plurality of individually driven transducer elements whose phases (and, optionally, amplitudes) can each be controlled independently from one another and, thus, can be set so as to result in constructive interference of the individual acoustic waves in the focal zone. Such a “phased-array” transducer facilitates steering the focal zone to different locations by adjusting the relative phases between the transducers, and generally provides the higher a focus quality and resolution, the greater the number of transducer elements. Magnetic resonance imaging (MRI) may be utilized to visualize the focus and target in order to guide the ultrasound beam.


The relative phases at which the transducer elements need to be driven to result in a focus at the target location depend on the relative location and orientation of the transducer surface and the target, as well as on the dimensions and acoustic material properties (e.g., sound velocities) of the tissue or tissues between them (i.e., the “target tissue”). Thus, to the extent the geometry and acoustic material properties are known, the relative phases (and, optionally, amplitudes) can be calculated, as described, for example, in U.S. Pat. No. 6,612,988 (filed Dec. 15, 2000), U.S. Pat. No. 6,770,031 (filed Aug. 26, 2002), and U.S. Pat. No. 7,344,509 (filed Apr. 9, 2004), as well as U.S. patent application Ser. No. 12/425,698 (filed on Apr. 17, 2009), the entire disclosures of which are hereby incorporated by reference. In practice, however, knowledge of these parameters is often too incomplete or imprecise to enable high-quality focusing based on computations of the relative phases alone. For example, when ultrasound is focused into the brain to treat a tumor, the skull in the acoustic path may cause aberrations that are not readily ascertainable. In such situations, treatment is typically preceded by an auto-focusing procedure in which, iteratively, an ultrasound focus is generated at or near the target, the quality of the focus is measured (using, e.g., thermal imaging or acoustic radiation force imaging (ARFI)), and experimental feedback is used to adjust the phases of the transducer elements to achieve sufficient focus quality.


The number of sonications in this procedure is typically at least three times the number of individually controlled transducer elements, and even more sonications may be needed to overcome measurement noise. The auto-focusing procedure may thus take a substantial amount of time, which may render it impracticable or, at the least, inconvenient for a patient. Further, during the auto-focusing sonications, ultrasound energy is inevitably deposited into the tissue at and surrounding the target, potentially damaging healthy tissue. While the effect of pre-therapeutic sonications may be minimized by employing an imaging technique that requires only low acoustic intensity (e.g., ARFI), it is generally desirable to limit the number of sonications prior to treatment. Accordingly, there is a need for more efficient ways of focusing a phased array of transducer element to create a high-quality ultrasound focus.


SUMMARY

The present invention provides, in various embodiments, systems and methods for focusing ultrasound by adjusting the phases and, optionally, amplitudes of a phased array of transducer elements based on a combination of (i) a-priori knowledge about the relative location and/or orientation between the transducer surface and the target, the dimensions and/or acoustic material properties of the target tissue, and/or any quantities derived from these parameters (hereinafter collectively referred to as a “sonication model”), and (ii) experimental feedback about the focus quality. Using focus measurements to adjust the transducer elements may improve focus quality over purely computational approaches, while employing computations based on a sonication model may reduce the number of sonications (and, thus, the time and energy needed to achieve a given focus quality).


In some embodiments, transducer elements are grouped into sub-arrays, and each sub-array is treated, for purposes of experimental phase adjustments, as a single element. Such grouping reduces the number of independently controllable elements and, consequently, the optimization time and energy. While, in general, fewer elements result in lower resolution and, hence, lower focus quality, this undesirable effect may be avoided or minimized by “smart grouping” based on the sonication model (e.g., based on the incidence angle of ultrasound from a sub-array onto a target tissue interface, i.e., an outer surface of the target tissue or an interface between multiple layers of the target tissue). Smart grouping involves keeping the array resolution (i.e., the number of independently controllable elements per unit area) high in regions where finer adjustments may be needed.


In some embodiments, a model of the target tissue is developed, and uncertainties in the model (e.g., uncertainties about the values of certain geometric or material parameters) are captured in one or more variable model parameters. The model parameters are then varied discretely over ranges that are expected to include the unknown true parameter values, and for each discrete set of parameter values, the phases (and amplitudes) of the transducer elements are computed for a given focus target, the transducers are driven accordingly, and the resulting focus quality is measured. The set of parameter values that yields the best focus is adopted, and may subsequently be used to compute the relative transducer element phases for therapeutic sonications of the target. Often, relatively few sonications—compared with the number required for auto-focusing without a-priori knowledge—will suffice to find an approximation of the model parameter values that results in an acceptable focus quality.


In a first aspect, a method of focusing a phased array of ultrasound transducer elements into a target tissue, in accordance with various embodiments, involves grouping the transducer elements into sub-arrays based on a sonication model, and determining relative phases of the transducer elements within each sub-array. Further, the method includes driving the transducer elements of the sub-arrays at the respective relative phases to generate sub-foci, determining whether the sub-foci constructively interfere, and, if not, adjusting the phases of the transducer elements to cause constructive interference of the sub-foci.


The sonication model may include a geometric parameter indicative of a relative arrangement between the phased array and the target tissue; a target focus location; and/or one or more material parameters and/or geometric parameters of the target tissue, which may be obtained by measurements using, e.g., MRI or computer tomography. Grouping may be based on incidence angles of ultrasound emitted from the transducer elements on a target tissue interface. The relative phases of the transducer elements within a sub-array may be computed based on the sonication model, and/or may be determined experimentally by driving the transducer elements of the sub-array so as to generate a sub-focus, measuring a quality of the sub-focus, and adjusting the relative phases to improve the quality of the sub-focus.


Determining whether the sub-foci constructively interfere may involve determining whether the sub-foci are in phase and/or whether they are co-located. If the sub-foci are not in phase, the phases of the transducer elements may be adjusted by applying phase shifts of equal magnitude to the transducer elements within each sub-array, and choosing the phase shifts applied to respective sub-arrays so as to bring the sub-foci in phase. If the sub-foci are not co-located, adjusting the phases of the transducer elements may include applying phase gradients across the transducer elements of each sub-array so as to co-locate the sub-foci. In some embodiments, the determination whether the sub-foci constructively interfere includes measuring a quality of a global focus formed by the sub-foci, e.g., by measuring a tissue displacement associated with the global focus, using magnetic-resonance acoustic radiation force imaging (MR-ARFI).


In a second aspect, various embodiments provide a method of focusing a phased array of ultrasound into a target tissue using a model of the target tissue that includes one or more model parameters (e.g., the velocity of sound). The method involves, for each of a plurality of value sets for the model parameter(s), the steps of computing relative phases of the transducer elements based (at least in part) on the model and a target focus location in the target tissue, driving the transducer elements at the computed relative phases so as to generate an ultrasound focus at the target focus location, and measuring the quality of the focus (e.g., by measuring a tissue displacement associated with the focus using ARFI). Among the plurality of value sets, the set associated with the highest focus quality is selected. The transducer elements may then be driven at relative phases computed based on the model, the selected model parameter value set, and the target focus location.


The method may further include the step of obtaining the model of the target tissue, for instance, by measuring a material property and/or a geometric characteristic of the target tissue (using, e.g., MRI or computer tomography). In some embodiments, the model includes a plurality of model parameters, and each of the value sets comprises a value for each of the model parameters. In other embodiments, the model includes a single model parameter, and each of the value sets comprises a value for the single model parameter.


In a third aspect, various embodiments are directed to a system for focusing ultrasound into a target tissue using a sonication model. The system includes a phased array of ultrasound transducer elements for generating an ultrasound focus in the target tissue, a system (e.g., an MRI system) for imaging the ultrasound focus, and a control facility in communication with the MRI system and the phased array of transducer elements. The control facility is configured to receive data associated with the sonication model, compute relative phases of the transducer elements based at least in part on the data, drive the transducer elements at the relative phases so as to generate the ultrasound focus, and adjust the relative phases, based at least in part on an image of the ultrasound focus, so as to improve the ultrasound focus.


In some embodiments, the control facility is configured to group the transducer elements into sub-arrays and compute relative phases of the transducer elements within each sub-array. Further, the control facility may be configured to adjust the relative phases so as to cause constructive interference of sub-foci generated by the sub-arrays.


In some embodiments, the data includes multiple value sets for at least one model parameter of the sonication model. The control facility may be configured to compute relative phases of the transducer elements and drive the transducer elements at the relative phases sequentially for the multiple value sets of the model parameter(s). Further, the control facility may be configured to measure a quality of the focus for each of the multiple value sets and to select, among the multiple value sets, the set associated with the highest focus quality.


In a third aspect, various embodiments are directed to an ultrasound focusing system for use in connection with an imaging system. The system includes a phased array of ultrasound transducer elements for generating an ultrasound focus in the target tissue; and a control facility configured to (i) receive data associated with a sonication model, (ii) based at least in part on the data, compute relative phases of the transducer elements, (iii) drive the transducer elements at the relative phases so as to generate the ultrasound focus, and (iv) based at least in part on an image of the ultrasound focus provided by the imaging system, adjust the relative phases so as to improve the ultrasound focus. The imaging system may be a magnetic resonance imaging system.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing will be more readily understood from the following detailed description of the invention in conjunction with the drawings, wherein:



FIG. 1 is a schematic drawing illustrating a magnetic-resonance-guided focused ultrasound system (MRgFUS) in accordance with various embodiments;



FIGS. 2A-2C illustrate several magnetic-resonance ARFI sequences in accordance with various embodiments;



FIG. 3A is an image of material displacements in an ultrasound focus region in accordance with some embodiments;



FIG. 3B is a graph illustrating material displacement in the focus center as a function of the phase of an individual transducer element, as it may be used in calibrations methods in accordance with various embodiments; and



FIG. 4 is a schematic drawing of a transducer arrangement for brain tumor treatment, illustrating smart grouping of transducer elements in accordance with one embodiment;



FIG. 5 is an MR image of a female breast, illustrating tissue properties relevant to focusing ultrasound for breast cancer treatment in accordance with one embodiment;



FIG. 6A is a flow chart illustrating an ultrasound focusing method involving smart grouping of transducer element in accordance with one embodiment; and



FIG. 6B is a flow chart illustrating an ultrasound focusing method involving experimentally determining parameter values of a target tissue model in accordance with one embodiment.





DETAILED DESCRIPTION


FIG. 1 illustrates schematically an exemplary MRgFUS 100 in accordance with various embodiments of the invention. The system includes an ultrasound transducer 102, which is disposed near the torso 104 of a patient and directed towards a target 106 in a region of interest (“ROI”) inside the patient. The transducer 102 may comprise a one- or two-dimensional array (i.e., a row or a matrix) of individually controllable transducer elements 108. In other embodiments, the transducer elements 108 may be arranged in a non-coordinated fashion, i.e., they need not be spaced regularly or arranged in a regular pattern. The transducer may have a curved (e.g., spherical or parabolic) shape, as illustrated, or may include one or more planar or otherwise shaped sections. Its dimensions may vary, depending on the application, between millimeters and tens of centimeters. The transducer elements 108 may be piezoelectric ceramic elements. Piezo-composite materials, or generally any materials capable of converting electrical energy to acoustic energy, may also be used. To damp the mechanical coupling between the elements 108, they may be mounted on the housing using silicone rubber or any other suitable damping material.


The transducer elements 108 are separately controllable, i.e., they are each capable of emitting ultrasound waves at amplitudes and/or phases that are independent of the amplitudes and/or phases of the other transducers. A control facility 110 in communication with the array serves to drive the transducer elements 108. For n transducer elements 108, the control facility 110 may contain n control circuits, each comprising an amplifier and a phase delay circuit and driving one of the transducer elements. The control facility 110 may split a radio frequency (RF) input signal, typically in the range from 0.1 MHz to 4 MHz, to provide n channels for the n control circuits. The control facility may be configured to drive the individual transducer elements 108 at the same frequency, but at different phases and different amplitudes so that they collectively produce a focused ultrasound beam. The control facility 110 may also include additional circuitry and switches that allow subsets of the transducer elements to be grouped into sub-arrays, and the elements within one sub-array to be driven at the same amplitude and phase.


The control facility 110 desirably provides computational functionality, which may be implemented in software, hardware, firmware, hardwiring, or any combination thereof, to compute the required phases and amplitudes for a desired focus location. For example, the control facility 110 may receive data indicative of the desired focus location (i.e., the target) relative to the ultrasound transducer, and account for the respective distances between each transducer element and the target, and the associated travel times of the acoustic waves that originate at the various transducer elements, in computing the phases. If the sum of the transducer element phase and the phase acquired between the transducer element and the target (i.e., the product of the frequency and the travel time of the wave, modulo 2π) is the same for all elements, the waves from the different transducer elements constructively interfere at the target. Since the travel time of a wave depends on the velocity of sound between the transducer element and the target, which is generally different for different tissues, the phase computation may be based on a model of the target tissue that contains information about the thicknesses and sound velocities of the various tissue layers that form the target tissue.


In general, the control facility may include several separable apparatus, such as a frequency generator, a beamformer containing the amplifier and phase delay circuitry, and a computer (e.g., a general-purpose computer) performing the computations and communicating the phases and amplitudes for the individual transducer elements 108 to the beamformer(s). Such systems are readily available or can be implemented without undue experimentation.


The MRgFUS system 100 further includes an MRI apparatus in communication with the control facility 110. The apparatus may include a cylindrical electromagnet 114, which generates a static magnetic field within a bore thereof. During medical procedures, the patient may be placed inside the bore on a movable support table, and positioned such that an imaging region encompassing the ROI (e.g., a particular organ) falls within a region where the magnetic field is substantially uniform. The magnetic field strength within the uniform region is typically between about 1.5 and about 3.0 Tesla. The magnetic field causes hydrogen nuclei spins to align and precess about the general direction of the magnetic field. An RF transmitter coil 116 surrounding the imaging region emits RF pulses into the imaging region, causing some of the aligned spins to oscillate between a temporary high-energy non-aligned state and the aligned state. This oscillation induces RF response signals, called the magnetic-resonance (MR) echo or MR response signals, in a receiver coil, which may, but need not, be the transmitter coil 116. The MR response signals are amplified, conditioned, and digitized into raw data using an image processing system (which may be implemented, e.g., in control facility 110), and further transformed into arrays of image data by methods known to those of ordinary skill in the art. Based on the image data, the target 106 (e.g., a tumor) is identified. The ultrasound transducer 102 is then driven so as to focus ultrasound into (or near) the treatment region.


To confirm the location and measure the quality of the focus, the focus may be visualized using one of a number of MR-based imaging techniques, such as, e.g., thermal MRI or MR-ARFI. Because MR-ARFI generally requires lower ultrasound energies during alignment and calibration procedures than other methods, and the ultrasound intensity preceding the actual treatment should be minimized to avoid damage to tissue outside the target, MR-ARFI is typically preferred. In MR-ARFI, a transducer is driven so as to focus an ultrasound wave pulse into the body at or near the target. The ultrasound wave exerts acoustic radiation pressure onto the material along its path. At the focus, where the waves converge, this pressure is highest, resulting in a temporary local displacement of the material in the longitudinal direction and/or in shear waves that propagate radially away from the focus. Thus, the ultrasound pressure creates a displacement field that directly reflects the acoustic field. The displacement field may be visualized by applying transient-motion or displacement-sensitizing magnetic field gradients to the imaging region by gradient coils, which are part of standard MRI systems and are typically located near the cylindrical electromagnet 114. When the ultrasound pulse is applied in the presence of such gradients, the resulting displacement is directly encoded into the phase of the MR response signal. For example, the gradient coils and transducer may be configured such that the ultrasound pulse pushes material near the focus towards regions of the magnetic field with higher field strengths. In response to the resulting change in the magnetic field, the phase of the MR response signal changes proportionally, thereby encoding in the signal the displacement caused by the ultrasound radiation pressure.


To achieve high image contrast, the ultrasound pulse, encoding gradients, and RF pulse are precisely timed with respect to each other according to a suitable displacement-encoding sequence. FIGS. 2A-2C illustrate five exemplary MR-ARFI sequences that may be used in embodiments of the invention. These sequence diagrams illustrate the order in which the displacement-encoding magnetic field gradients (thin solid lines), ultrasound pulses (dotted lines), and RF pulses (thick solid lines) appear in time. Three different field gradient sets are shown: two single lobes (a), repeated bipolars (b), and inverted bipolars (c). For gradient set (a), ultrasound may be applied during either the first or the second lobe. Similarly, for gradient set (c), ultrasound may be applied during the first or the second halves of the bipolars. In general, MR-ARFI sequences utilize magnetic field gradients that are synchronized with the ultrasound pulses. In preferred embodiments, a sequence like the repeated bipolar sequence (b) shown in FIG. 2B may be used. The imaging sequence may be programmed into the control facility 110. The control facility 110 may then send trigger signals to the ultrasound transducer and the MRI hardware to ensure correct timing between the signals.


An example of an MR-ARFI image of an ultrasound focus region is shown in FIG. 3A. As shown, the material displacement with respect to an equilibrium position varies between about −1 μm and 5 μm. In general, the stronger the acoustic field intensity, the greater will be the maximum displacement at the center of the focus. The acoustic field intensity, in turn, is maximized when the individually controlled portions of the transducer (i.e., the elements within a transducer segments and/or the various segments) emit acoustic waves that are all in phase at the focus position. If a transducer element is out of phase with respect to the others, the focus intensity in the center decreases. This relationship can be exploited to optimize the focus, and thus to map and adjust the transducer elements and/or segments, as detailed further below. Assuming, for example, that all but one of the transducer elements of a segment are properly configured, the correct phase of the last element can be determined by tuning the phase over a full cycle (e.g., between −π and +π), measuring for each phase the displacement in the focus center, and then setting the phase to the value corresponding to the maximum displacement. FIG. 3B depicts the results of such an adjustment procedure. In the illustrated example, the material displacement over the full phase cycle of one element varies between about 4.85 μm and about 5.4 μm. The maximum displacement occurs at about 0.12 rad. Consequently, the focus intensity and quality can be improved by introducing a phase shift of 0.12 rad for the tested transducer element.


MR-ARFI may be used to “auto-focus” an ultrasound beam (i.e., to iteratively improve the focus quality of a pre-focused beam based on experimental feedback) in advance of the therapeutic application of ultrasound. Consider, for example, the treatment of a brain tumor with ultrasound. A transducer for such an application is usually large; it may surround a wide area of the skull and comprise a large number of elements (e.g., 1000). In preparation for treatment, the transducer is typically placed in a stable position relative to the patient's head, and the transducer elements are then activated at relative phases based on the sonication geometry (which generally includes the relative position and orientation of transducer and the target tissue, as well as the target location). Optionally, phase corrections may be applied to the transducer elements to compensate for tissue aberrations, which are mostly caused by the intervening skull tissue and which may vary significantly with location. The phase corrections may be computed based on skull-imaging data obtained, for example, through computer tomography or MRI, which provide estimates of the local skull bone thickness and density. Often, such computational correction for skull-based aberrations results in a noticeable, yet insufficient improvement of the focus quality. The focus may be optimized with an auto-focusing procedure, in which low-energy ultrasound is focused at (or near) the target, and a quantity correlated to the focus quality (e.g., the peak displacement caused by radiation force) is measured.


Auto-focusing typically involves a systematic series of sonications for various transducer phasing combinations. Without further information, it may take about 3000 or more sonications to optimize the focus of an array with 1000 elements. However, a-priori information capable of reducing the required number of sonications may be available. Such a-priori information may include a model of the target tissue, which may provide detailed information about the components of the target tissue (such as various tissue layers), their relative arrangement, and the associated material types, densities, and structures, and/or various material parameter values. A target tissue model may be developed based on images of the target tissue, and/or generally known or experimentally determined material parameters and physical properties of certain tissue types and/or interfaces between tissue layers (such as, e.g., coefficients of reflection at an interface between bone and soft tissue). In addition, a-priori information may include relevant parameters of the sonication geometry, i.e., the location and orientation of the transducer with respect to the target tissue. The sonication geometry may be known from mechanical constraints (such as, e.g., a rigid transducer structure that is placed in contact with the target tissue), or measured using fiducials or sensors embedded in the transducer, such as MR tracking coils or position sensors (e.g., tilt indicators, ultrasound, or optical encoders). Using such a-prior information, the relative phases between transducer elements that are required for a particular target are often predictable in the vicinity of a particular location at the transducer. On the other hand, the relative phases between groups of transducers that are further apart from one another may require adjustment.



FIG. 4 illustrates schematically an exemplary sonication geometry for ultrasound focusing into the brain. A curved transducer 400 is placed above a patient's skull 402 and driven so as to focus ultrasound from many directions onto a target 404. In this arrangement, the incidence angle of ultrasound onto the skull varies greatly, between 0° (perpendicular incidence) and about 40°. The incidence angle has been found to be a major determining factor for the reliability of phase corrections computed with a sonication model derived from computer tomography or MRI data. For incidence angles below about 15° and above about 35°, the phase corrections are usually highly reliable. For incidence angles in a critical range between about 15° and about 35° (corresponding to region 406 in FIG. 4), experimental adjustment of phases is desirable. Therefore, one approach to combining a-priori knowledge with experimental feedback involves segmenting the transducer array (or, in other words, grouping the transducer elements) into sub-arrays according to incidence angle. Sub-arrays associated with incidence angles that do not allow for reliable prediction may consist of only few or, in the extreme case, individual transducer elements, whereas sub-arrays associated with low (e.g., <15° or high (e.g., >35° incidence angles typically include many elements—and generally the higher the degree of predictability, the more elements may be combined in a sub-array.


As a person of skill in the art will appreciate, the smart-grouping approach outlined above may be modified depending on the particular application. For example, the critical range of incidence angles may differ from the one used in the above example. Further, the grouping of transducer elements need not be based on incidence angles at all, but may, generally, be based on other parameters of the sonication model that affect the reliability of computationally determined transducer element phases. For instance, the grouping may be based on the predominant type of tissue that an acoustic wave traverses to reach the focus location. Tissue type is relevant, for example, in the treatment of breast cancer, as illustrated in FIG. 5. The figure shows an MRI image of the breast 500 of a woman in prone position, which is to be treated from below as indicated by the arrows 502. A set of many MRI images would be needed for three-dimensional information. The ultrasound beam, which originates from a transducer surface 504, generally passes through both fatty and non-fatty tissues, which have different sound velocities. These variations in velocity may cause aberrations that disturb the focus. The aberrations may be reduced by calculating time delays for each transducer element from the MRI image(s), and compensating for the time delays with corresponding phase shifts. To increase the accuracy of the calculated time delays, the transducer may be partitioned into sub-arrays whose acoustic waves travel through mostly fatty or mostly non-fatty tissue, respectively.



FIG. 6A illustrates, in a flow chart, a method of focusing a transducer array using smart grouping. After the transducer elements have been grouped into sub-arrays (step 600), each sub-array may be driven so as to create a discrete sub-focus at or near the target, such as, e.g., target 404 in FIG. 4 (step 602). The relative phases (and amplitudes) of the elements within a sub-array may be computed based on the sonication model (i.e., information about the local geometry and tissue properties). In some embodiments, the sub-foci of one or more sub-arrays are further improved using auto-focusing with focus quality feedback. For example, in the context of focusing ultrasound into the brain as shown in FIG. 4, instead of sub-dividing the transducer into individual transducer elements at locations corresponding to incidence angles in the critical regime (where a high resolution is generally required), the transducer elements may be grouped into a sub-array, their relative phases adjusted using, e.g., MR-ARFI, and the sub-array subsequently treated as only one element.


Once the relative phases within the sub-arrays are properly set, the quality of the global focus, which is the superposition of the sub-foci, may be measured (step 604), e.g., using MR-ARFI. An optimal global focus is achieved when the sub-foci constructively interfere, i.e., when they are co-located and in phase. In many (but not all) applications, adjusting the overall phase of each sub-array will suffice to achieve constructive interference because creating the sub-foci at the target location will already guarantee their geometric overlap. If the sub-foci are not sufficiently co-located (due to a deviation of their location from the target location), their relative positions may be adjusted by steering the respective ultrasound beams to the desired location (step 606). Steering involves applying phase gradients to the sub-arrays, which changes the relative phases between transducer elements within a sub-array, but in a constrained way that preserves most of the information about relative phases. To bring the sub-foci in phase, phase shifts may be applied to the sub-arrays (step 608). (Applying a phase shift to a sub-array involves applying that phase shift to each element within the sub-array.) When the focus quality is sufficient, i.e., the sub-foci constructively interfere, the transducer may be employed in treating the target (step 610).


A different approach to using information of the target tissue and supplementing it with experimental feedback on the focus quality involves modeling the target tissue with variable parameters. Such a target-tissue model may account for the fact that some parameters are better known than others. For example, the MR image shown in FIG. 5 provides good information about the thickness of the various tissues, such as water, fatty tissue, and non-fatty tissue, along the acoustic rays originating at different transducer locations. However, while the sound velocity of water is well-known, the sound velocities of fatty and non-fatty tissues are only known within comparatively large intervals of uncertainty, and generally vary between patients. Thus, the time delays for the different acoustic rays are also uncertain. The degree of uncertainty may, however, be reduced indirectly by computing the relative phases for different values of the sound velocities within the known ranges, and comparing the quality of the resulting foci (again, using MR-ARFI or another technique to measure focus parameters indicative of the quality). The sound velocity values that result in the best focus (among the ones measured and compared) may then be assumed to be good approximations of the true sound velocities.


More generally, focus quality feedback may be used to supplement an incomplete target tissue model with N unknown parameters. For each unknown parameter vi, the interval of uncertainty may be sampled with ki values. For example, in the breast treatment case, where N=2, the sound velocity of fatty tissue and the sound velocity of non-fatty tissue may each be sampled with k1=k2=5 values. Exploring the entire discrete two-dimensional space of parameter values will then require 25 sonications—significantly fewer than would typically be needed to adjust the transducer element phases without using any a-priori information about the target tissue. Determining values of tissue model parameters using MR-ARFI feedback may thus, in certain applications, provide a viable alternative to smart grouping for the purpose of achieving high focus quality with a reduced number of calibration sonications.



FIG. 6B illustrates a method of using a target tissue model in combination with experimental feedback to improve the quality of an ultrasound focus. The first step 650—providing the model—may be accomplished, for example, by imaging the target tissue with the MRI apparatus to determine the thicknesses and locations of various tissue layers, and supplying this information to the control facility. Then, model parameters that are not known a priori are assigned arbitrary values within ranges in which the true values are expected to lie (step 652), the relative phases are adjusted based on the model and the selected parameter values (step 654), and the transducer is focused (step 656) and the focus quality measured (step 656). These steps are repeated for multiple value sets of the parameters. The focus qualities for different value sets are then compared, and the value set that corresponds to the best focus is selected. Once the target tissue model has thus been supplemented, the transducer may be driven in accordance with the model to sonicate and thereby treat the target (step 662).


Although the present invention has been described with reference to specific details, it is not intended that such details should be regarded as limitations upon the scope of the invention, except as and to the extent that they are included in the accompanying claims.

Claims
  • 1. A system for focusing ultrasound into a target tissue using a sonication model, the system comprising: a phased array of ultrasound transducer elements configured to generate an ultrasound focus in the target tissue;an imaging system configured to image the ultrasound focus; andin communication with the imaging system and the phased array of transducer elements, a control facility configured to set relative phases between the transducer elements so as to create a global focus from a plurality of sub-foci, the facility being configured to (i) receive data associated with the sonication model, the data comprising a parameter including at least one of an incidence angle or a predominant type of the target tissue and affecting a reliability of computational phase determinations, (ii) based at least in part on the parameter, group the transducer elements into sub-arrays, at least one of the sub-arrays comprising multiple transducer elements, and compute relative phases of the transducer elements within each sub-array, (iii) drive the transducer elements of the sub-arrays at the respective computed relative phases so as to generate the ultrasound sub-foci, each of which is associated with one of the sub-arrays, and (iv) based at least in part on an image of the ultrasound sub-foci, adjust the relative phases so as to cause constructive interference of the ultrasound foci, thereby generating the global focus.
  • 2. The system of claim 1, wherein the imaging system is a magnetic resonance imaging system.
  • 3. A system for use in connection with an imaging system and for focusing ultrasound into a target tissue using a sonication model, the system comprising: a phased array of ultrasound transducer elements configured to generate an ultrasound focus in the target tissue; anda control facility configured to set relative phases between the transducer elements so as to create a global focus from a plurality of sub-foci, the facility being configured to (i) receive data associated with the sonication model, the data comprising a parameter including at least one of an incidence angle or a predominant type of the target tissue and affecting a reliability of computational phase determinations, (ii) based at least in part on the parameter, group the transducer elements into sub-arrays, at least one of the sub-arrays comprising multiple transducer elements, and compute relative phases of the transducer elements within each sub-array, (iii) drive the transducer elements of the sub-arrays at the respective computed relative phases so as to generate the ultrasound sub-foci, each of which is associated with one of the sub-arrays, and (iv) based at least in part on an image of the ultrasound sub-foci provided by the imaging system, adjust the relative phases so as to cause constructive interference of the ultrasound foci, thereby generating the global focus.
US Referenced Citations (248)
Number Name Date Kind
2795709 Camp Jun 1957 A
3142035 Harris Jul 1964 A
3942150 Booth et al. Mar 1976 A
3974475 Burckhardt et al. Aug 1976 A
3992693 Martin et al. Nov 1976 A
4000493 Spaulding et al. Dec 1976 A
4074564 Anderson Feb 1978 A
4206653 LeMay Jun 1980 A
4211132 Nichols, III et al. Jul 1980 A
4307613 Fox Dec 1981 A
4339952 Foster Jul 1982 A
4454597 Sullivan Jun 1984 A
4478083 Hassler et al. Oct 1984 A
4505156 Questo Mar 1985 A
4526168 Hassler et al. Jul 1985 A
4537074 Dietz Aug 1985 A
4549533 Cain et al. Oct 1985 A
4554925 Young Nov 1985 A
4662222 Johnson May 1987 A
4817614 Hassler et al. Apr 1989 A
4858597 Kurtze et al. Aug 1989 A
4865042 Umemura et al. Sep 1989 A
4888746 Wurster et al. Dec 1989 A
4889122 Watmough et al. Dec 1989 A
4893284 Magrane Jan 1990 A
4893624 Lele Jan 1990 A
4937767 Reuschel et al. Jun 1990 A
5197475 Antich et al. Mar 1993 A
5209221 Riedlinger May 1993 A
5211160 Talish et al. May 1993 A
5247935 Cline et al. Sep 1993 A
5271400 Dumoulin et al. Dec 1993 A
5275165 Ettinger et al. Jan 1994 A
5291890 Cline et al. Mar 1994 A
5307812 Hardy et al. May 1994 A
5307816 Hashimoto et al. May 1994 A
5318025 Dumoulin et al. Jun 1994 A
5323779 Hardy et al. Jun 1994 A
5327884 Hardy et al. Jul 1994 A
5329930 Thomas, III et al. Jul 1994 A
5368031 Cline et al. Nov 1994 A
5368032 Cline et al. Nov 1994 A
5379642 Reckwerdt et al. Jan 1995 A
5391140 Schaetzle et al. Feb 1995 A
5413550 Castel May 1995 A
5435312 Spivey et al. Jul 1995 A
5443068 Cline et al. Aug 1995 A
5474071 Chapelon et al. Dec 1995 A
5485839 Aida et al. Jan 1996 A
5490840 Uzgiris et al. Feb 1996 A
5507790 Weiss Apr 1996 A
5520188 Hennige et al. May 1996 A
5520612 Winder et al. May 1996 A
5526814 Cline et al. Jun 1996 A
5549638 Burdette Aug 1996 A
5553618 Suzuki et al. Sep 1996 A
5573497 Chapelon Nov 1996 A
5582578 Zhong et al. Dec 1996 A
5590653 Aida et al. Jan 1997 A
5590657 Cain et al. Jan 1997 A
5601526 Chapelon et al. Feb 1997 A
5605154 Ries et al. Feb 1997 A
5606971 Sarvazyan Mar 1997 A
5617371 Williams Apr 1997 A
5617857 Chader et al. Apr 1997 A
5643179 Fujimoto Jul 1997 A
5662170 Donovan et al. Sep 1997 A
5665054 Dory Sep 1997 A
5666954 Chapelon et al. Sep 1997 A
5676673 Ferre et al. Oct 1997 A
5687729 Schaetzle Nov 1997 A
5694936 Fujimoto et al. Dec 1997 A
5711300 Schneider et al. Jan 1998 A
5722411 Suzuki et al. Mar 1998 A
5728062 Brisken Mar 1998 A
5739625 Falcus Apr 1998 A
5743863 Chapelon Apr 1998 A
5752515 Jolesz et al. May 1998 A
5759162 Oppelt et al. Jun 1998 A
5762616 Talish Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5784336 Gopinathan et al. Jul 1998 A
5810008 Dekel et al. Sep 1998 A
5810731 Sarvazyan et al. Sep 1998 A
5873845 Cline et al. Feb 1999 A
5897495 Aida et al. Apr 1999 A
5904659 Duarte et al. May 1999 A
5938600 Van Vaals et al. Aug 1999 A
5938608 Bieger et al. Aug 1999 A
5947900 Derbyshire et al. Sep 1999 A
5984881 Ishibashi et al. Nov 1999 A
6004269 Crowley et al. Dec 1999 A
6023636 Wendt et al. Feb 2000 A
6042556 Beach et al. Mar 2000 A
6071239 Cribbs et al. Jun 2000 A
6113559 Klopotek Sep 2000 A
6128522 Acker et al. Oct 2000 A
6128958 Cain Oct 2000 A
6135960 Holmberg Oct 2000 A
6193659 Ramamurthy et al. Feb 2001 B1
6217530 Martin et al. Apr 2001 B1
6242915 Hurd Jun 2001 B1
6246896 Dumoulin et al. Jun 2001 B1
6263230 Haynor et al. Jul 2001 B1
6267734 Ishibashi et al. Jul 2001 B1
6289233 Dumoulin et al. Sep 2001 B1
6309355 Cain et al. Oct 2001 B1
6317619 Boernert et al. Nov 2001 B1
6322527 Talish Nov 2001 B1
6334846 Ishibashi et al. Jan 2002 B1
6374132 Acker et al. Apr 2002 B1
6392330 Zloter et al. May 2002 B1
6397094 Ludeke et al. May 2002 B1
6413216 Cain et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6424597 Bolomey et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6428532 Doukas et al. Aug 2002 B1
6433464 Jones Aug 2002 B2
6461314 Pant et al. Oct 2002 B1
6475150 Haddad Nov 2002 B2
6478739 Hong Nov 2002 B1
6506154 Ezion et al. Jan 2003 B1
6506171 Vitek et al. Jan 2003 B1
6511428 Azuma et al. Jan 2003 B1
6522142 Freundlich Feb 2003 B1
6523272 Morales Feb 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6559644 Froundlich et al. May 2003 B2
6566878 Komura et al. May 2003 B1
6582381 Yehezkeli et al. Jun 2003 B1
6599256 Acker et al. Jul 2003 B1
6612988 Maor et al. Sep 2003 B2
6613004 Vitek et al. Sep 2003 B1
6613005 Friedman et al. Sep 2003 B1
6618608 Watkins et al. Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6629929 Jago et al. Oct 2003 B1
6645162 Friedman et al. Nov 2003 B2
6652461 Levkovitz Nov 2003 B1
6666833 Friedman et al. Dec 2003 B1
6676601 Lacoste et al. Jan 2004 B1
6676602 Barnes et al. Jan 2004 B1
6679855 Horn et al. Jan 2004 B2
6705994 Vortman et al. Mar 2004 B2
6719694 Weng et al. Apr 2004 B2
6733450 Alexandrov et al. May 2004 B1
6735461 Vitek et al. May 2004 B2
6761691 Tsuzuki Jul 2004 B2
6770031 Hynynen et al. Aug 2004 B2
6770039 Zhong et al. Aug 2004 B2
6788619 Calvert Sep 2004 B2
6790180 Vitek Sep 2004 B2
6824516 Batten et al. Nov 2004 B2
6951540 Ebbini et al. Oct 2005 B2
6961606 DeSilets et al. Nov 2005 B2
7001379 Behl et al. Feb 2006 B2
7077820 Kadziauskas et al. Jul 2006 B1
7094205 Marmarelis Aug 2006 B2
7128711 Medan et al. Oct 2006 B2
7155271 Halperin et al. Dec 2006 B2
7175596 Vitek et al. Feb 2007 B2
7175599 Hynynen et al. Feb 2007 B2
7264592 Shehada Sep 2007 B2
7264597 Cathignol Sep 2007 B2
7267650 Chow et al. Sep 2007 B2
7344509 Hynynen et al. Mar 2008 B2
7377900 Vitek et al. May 2008 B2
7429248 Winder et al. Sep 2008 B1
7452357 Vlegele et al. Nov 2008 B2
7505805 Kuroda Mar 2009 B2
7505808 Anderson et al. Mar 2009 B2
7507213 Schultheiss et al. Mar 2009 B2
7510536 Foley et al. Mar 2009 B2
7511501 Wexler Mar 2009 B2
7535794 Prus et al. May 2009 B2
7553284 Vaitekunas Jun 2009 B2
7603162 Danz et al. Oct 2009 B2
7611462 Vortman et al. Nov 2009 B2
7652410 Prus Jan 2010 B2
7699780 Vitek et al. Apr 2010 B2
20010031922 Weng et al. Oct 2001 A1
20020016557 Duarte et al. Feb 2002 A1
20020035779 Krieg et al. Mar 2002 A1
20020082589 Friedman et al. Jun 2002 A1
20020095087 Mourad et al. Jul 2002 A1
20020111552 Maor et al. Aug 2002 A1
20020161300 Hoff et al. Oct 2002 A1
20020188229 Ryaby et al. Dec 2002 A1
20030004439 Pant et al. Jan 2003 A1
20030060820 Maguire et al. Mar 2003 A1
20030187371 Vortman et al. Oct 2003 A1
20040030251 Ebbini et al. Feb 2004 A1
20040059265 Candy et al. Mar 2004 A1
20040068186 Ishida et al. Apr 2004 A1
20040122316 Satoh Jun 2004 A1
20040122323 Vortman et al. Jun 2004 A1
20040143187 Biagi et al. Jul 2004 A1
20040210134 Hynynen et al. Oct 2004 A1
20040210135 Hynynen et al. Oct 2004 A1
20040236253 Vortman et al. Nov 2004 A1
20040267126 Takeuchi Dec 2004 A1
20050033201 Takahashi et al. Feb 2005 A1
20050096542 Weng et al. May 2005 A1
20050131301 Peszynski et al. Jun 2005 A1
20050203444 Schonenberger et al. Sep 2005 A1
20050251046 Yamamoto et al. Nov 2005 A1
20060052661 Gannot et al. Mar 2006 A1
20060052701 Carter et al. Mar 2006 A1
20060052706 Hynynen et al. Mar 2006 A1
20060058678 Vitek et al. Mar 2006 A1
20060106300 Seppenwoolde et al. May 2006 A1
20060173385 Lidgren et al. Aug 2006 A1
20060184034 Haim et al. Aug 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060206105 Chopra et al. Sep 2006 A1
20060229594 Francischelli et al. Oct 2006 A1
20070016039 Vortman et al. Jan 2007 A1
20070055140 Kuroda Mar 2007 A1
20070066897 Sekins et al. Mar 2007 A1
20070073135 Lee et al. Mar 2007 A1
20070098232 Matula et al. May 2007 A1
20070167781 Vortman et al. Jul 2007 A1
20070197918 Vitek et al. Aug 2007 A1
20070219470 Talish et al. Sep 2007 A1
20070239062 Chopra et al. Oct 2007 A1
20080027342 Rouw et al. Jan 2008 A1
20080031090 Prus et al. Feb 2008 A1
20080033278 Assif Feb 2008 A1
20080082026 Schmidt et al. Apr 2008 A1
20080108900 Lee et al. May 2008 A1
20080125660 Yao et al. May 2008 A1
20080183077 Moreau-Gobard et al. Jul 2008 A1
20080228081 Becker et al. Sep 2008 A1
20080312562 Routh et al. Dec 2008 A1
20090088623 Vortman et al. Apr 2009 A1
20090118619 Oshiki May 2009 A1
20100030076 Vortman et al. Feb 2010 A1
20100056962 Vortman et al. Mar 2010 A1
20100125193 Zadicario May 2010 A1
20100179425 Zadicario Jul 2010 A1
20100268088 Prus et al. Oct 2010 A1
20100274130 Anand et al. Oct 2010 A1
20100318002 Prus et al. Dec 2010 A1
20110066032 Vitek et al. Mar 2011 A1
20110094288 Medan et al. Apr 2011 A1
Foreign Referenced Citations (51)
Number Date Country
4345308 Feb 2001 DE
0320303 Jun 1989 EP
0558029 Sep 1993 EP
1132054 Sep 2001 EP
1591073 Nov 2005 EP
1774920 Apr 2007 EP
1790384 May 2007 EP
1936404 Jun 2008 EP
2806611 Sep 2001 FR
5-92008 Apr 1993 JP
7-184907 Jul 1995 JP
7-231895 Sep 1995 JP
7-313518 Dec 1995 JP
11313833 Nov 1999 JP
00166940 Jun 2000 JP
01516075 Sep 2001 JP
02530145 Sep 2002 JP
WO-9100059 Jan 1991 WO
WO-9514505 Jun 1995 WO
WO-9852465 Nov 1998 WO
WO-0031614 Jun 2000 WO
WO-0158337 Aug 2001 WO
WO-0166189 Sep 2001 WO
WO-0180709 Nov 2001 WO
WO-0243805 Jun 2002 WO
WO-0244753 Jun 2002 WO
WO-02058791 Aug 2002 WO
WO-03013654 Feb 2003 WO
WO-03097162 Nov 2003 WO
WO-03098232 Nov 2003 WO
WO-2004093686 Nov 2004 WO
WO-2005058029 Jun 2005 WO
WO-2006018837 Feb 2006 WO
WO-2006025001 Mar 2006 WO
WO-2006087649 Aug 2006 WO
WO-2006119572 Nov 2006 WO
WO-2007051066 May 2007 WO
WO-2007073551 Jun 2007 WO
WO-2008039449 Apr 2008 WO
WO-2008050278 May 2008 WO
WO-2008075203 Jun 2008 WO
WO-2008119054 Oct 2008 WO
WO-2009055587 Apr 2009 WO
WO-2009081339 Jul 2009 WO
WO-2009094554 Jul 2009 WO
WO-2010058292 May 2010 WO
WO-2010082135 Jul 2010 WO
WO-2010119340 Oct 2010 WO
WO-2010143072 Dec 2010 WO
WO-2011013001 Feb 2011 WO
WO-2011024074 Mar 2011 WO
Non-Patent Literature Citations (57)
Entry
Fronheiser et al., “3D Acoustic Radiation Force Impulse (ARFI) Imaging Using a 2D Matrix Array: Feasibility Study,” Ultrasonics Symposium, pp. 1144-1147 (Oct. 2006).
Wu et al., “MRImaging of Shear Waves Generated by Focused Ultrasound,” Magnetic Resonance in Medicine, vol. 43, pp. 111-115 (2000).
Heikkila et al., “Simulations of Lesion Detection Using a Combined Phased Array LHMI-Technique,” Ultrasonics, IPC Science and Technology Press Ltd., vol. 48, No. 6-7, pp. 568-573 (Nov. 2008).
International Search Report and Written Opinion mailed Nov. 10, 2011 for International Application No. PCT/IB2011/001375 (13 pages).
McDonnald et al. “Usefulness of MR Imaging-Derived Thermometry and Dosimetry in Determining the Threshold for Tissue Damage INduced by Thermal Surgery in Rabbits,” Radiology, vol. 216, No. 2000 pp. 517-523 (2000).
Suprijanto et al. “Displacement Correction Scheme for MR-Guided Interstitial Laser Therapy,” Ellis RE, Peters TM (Eds.): MiCCAI , LNCS 2879, pp. 399-407 (2003).
Shmatukha et al. “Correction of Proton Resonance Frequencey Shift Temperature Maps for Magnetic Field Disturbances Caused by Breathing,” Physics in Medicine and Biology, vol. 51, No. 18 pp. 4689-4705 (2006).
De Senneville et al., “An Optimised Multi-Baseline Approach for On-Line MR-Temperature Monitoring on Commodity Graphics Hardware,” Biomedical Imaging, pp. 1513-1516 (2008).
Vigen et al., “Triggered, Navigated, Multi-Baseline Method for Proton Resonance Frequency Temperature Mapping with Respiratory Motion,” Magnetic Resonance in Medicine, vol. 50, pp. 1003-1010 (2003).
Botros et al., “A hybrid computational model for ultrasound phased-array heating in presence of strongly scattering obstacles,” IEEE Trans. on Biomed. Eng., vol. 44, No. 11, pp. 1039-1050 (Nov. 1997).
Cain et al., “Concentric-ring and Sector-vortex Phased-array Applicators for Ultrasound Hperthermia,” IEEE Trans. on Microwave Theory & Techniques, vol. MTT-34, No. 5, pp. 542-551 (May 1986).
Chen et al., “MR Acoustic Radiation Force Imaging: Comparison of Encoding Gradients.”
Cline et al., “Focused US system for MR imaging-guide tumor ablation,” Radiology, v. 194, No. 3, pp. 731-738 (Mar. 1995).
Cline et al., “MR Temperature mapping of focused ultrasound surgery,” Magnetic Resonance in Medicine, vol. 32, No. 6, pp. 628-636 (1994).
Cline et al., “Simultaneous magnetic resonance phase and magnitude temperature maps in muscle,” Magnetic Resonance in Medicine, vol. 35, No. 3, pp. 309-315 (Mar. 1996).
Daum et al., “Design and evaluation of a feedback based phased array system for ultrasound surgery,” IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 45, No. 2, pp. 431-434 (1998).
de Senneville et al., “Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focussed Ultrasound,” Magnetic Resonance in Medicine 57:319-330 (2007).
Fjield et al, “The Combined Concentric-ring and Sector-vortex Phased Array for MRI Guided Ultrasound Surgery,” IEEE Trans. on Ultrasonics, Ferroelectrics and Freq. Cont., vol. 44, No. 5, pp. 1157-1167 (Sep. 1997).
Herbert et al., “Energy-based adaptive focusing of waves: application to ultrasonic transcranial therapy,” 8th Intl. Symp. on Therapeutic Ultrasound.
Huber et al., “A New Noninvasive Approach in Breast Cancer Therapy Using Magnetic Resonance Imaging-Guided Focussed Ultrasound Surgery,” Cancer Research 61, 8441-8447 (Dec. 2001).
International Preliminary Report on Patentability in International Patent Application No. PCT/IB2004/001512, mailed Dec. 8, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2004/001498, dated Aug. 31, 2004.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2005/002273, mailed Dec. 20, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2005/002413, mailed Nov. 22, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2006/001641, mailed Sep. 25, 2006.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2006/003300, mailed Feb. 14, 2008.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/001079, mailed Dec. 10, 2007.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/002134, mailed Dec. 13, 2007.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/002140, mailed Dec. 29, 2008.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2008/003069, mailed Apr. 27, 2009.
Jolesz et al., “Integration of interventional MRI with computer-assisted surgery,” J. Magnetic Resonance Imaging. 12:69-77 (2001).
Kohler et al., “Volumetric HIFU Ablation guided by multiplane MRI thermometry,” 8th Intl. Symp. on Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009).
Kowalski et al., “Optimization of electromagnetic phased-arrays for hyperthermia via magnetic resonance temperature estimation,” IEEE Trans. on Biomed. Eng., vol. 49, No. 11, pp. 1229-1241 (Nov. 2002).
Maxwell et al., “Noninvasive thrombolysis using pulsed ultrasound cavitation therapy—Histotripsy,” Abstract, U.S. Natl. Lib. of Med., NIH, Ultrasound Med. Biol. (Oct. 23, 2009).
McDannold et al., “MRI evaluation of thermal ablation of tumors and focused ultrasounds,” JMRI vol. 8, No. 1, pp. 91-100 (1998).
McDannold et al., “Magnetic resonance acoustic radiation force imaging,” Med. Phys. vol. 35, No. 8, pp. 3748-3758 (Aug. 2008).
Medel et al., “Sonothrombolysis: An emerging modality for the management of stroke,” Neurosurgery, vol. 65, No. 5, pp. 979-993.
Mougenot et al., “MR monitoring of the near-field HIFU heating,” 8th Intl. Symp. on Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009).
Partial International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/001079, dated Sep. 25, 2007.
Vimeux et al., “Real-time control of focused ultrasound heating based on rapid MR thermometry,” Investig. Radiology, vol. 43, No. 3, pp. 190-193.
Vykhodtseva et al., “MRI detection of the thermal effects of focused ultrasound on the brain,” Ultrasound in Med. & Biol., vol. 26, No. 5, pp. 871-880 (2000).
Written Opinion in International Patent Application No. PCT/IL01/00340, mailed Feb. 24, 2003.
Written Opinion in International Patent Application No. PCT/IL02/00477, mailed Feb. 25, 2003.
Written Opinion in International Patent Application No. PCT/IB03/05551, mailed Sep. 10, 2004.
“How is Ablatherm treatment performed?” http://www.edap-hifu.com/eng/physicians/hifu/3c—treatment—treat-description.htm, accessed Jan. 3, 2003.
“What is HIFU? HIFU: High Intensity Focused Ultrasound,” http://www.edap-hifu.com/eng/physicians/hifu2a—hifu—overview.htm, accessed Jan. 3, 2003.
“What are the physical principles?” http://www.edap-hifu.com/eng/physicians/hifu/2c—hifu—physical.htm, accessed Jan. 3, 2003.
“How does HIFU create a lesion?” http://www.edap-hifu.com/eng/physicians/hifu/2d—hifu—lesion.htm, accessed Jan. 3, 2003.
“Prostate Cancer Phase I Clinical Trials Using High Intensity Focused Ultrasound (HIFU),” Focus Surgery, http://www.focus-surgery.com/PCT%20Treatment%20with%20HIFU.htm, accessed Jan. 3, 2003.
“Abstract” Focus Surgery, http://www.focus-surgery.com/Sanghvi.htm, accessed Jan. 3, 2003.
Exablate 2000 Specification, InSightec, Ltd. (2 pages).
FDA Approves Exablate 2000 as Non-invasive surgery for Fibroids, Oct. 22, 2004.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2010/000189, mailed Jun. 1, 2010.
International Search Report for PCT/IB03/05551 completion date Mar. 2, 2004 (5 pages).
International Search Report and Written Opinion in Internation Patent Application No. PCT/IB2010/000971, mailed Jul. 29, 2010 (9 pages).
First Office Action for 200680029730.8 PRC (7 pages).
McGough et al., “Direct Computation of Ultrasound Phased-Array Driving Signals from a Specified Temperature Distribution for Hyperthermia,” IEEE Transactions on Biomedical Engineering, vol. 39, No. 8, pp. 825-835 (Aug. 1992).
Related Publications (1)
Number Date Country
20110270136 A1 Nov 2011 US